Inventor · disambiguated record
Ralph R. Weichselbaum
Also filed as: WEICHSELBAUM RALPH · WEICHSELBAUM RALPH R
34 granted patents·35 pending applications·831 citations·filing 1992–2024
98Inventor score
Files withUNIV CHICAGO31ARCH DEV CORP15DANA FARBER CANCER INST INC6KHODAREV NIKOLAI2WEICHSELBAUM RALPH R2
Top patents by PatentIndex Score
69 records- 0195US7265356B2Image-guided medical intervention apparatus and methodUNIV CHICAGO·Filed 2004·Granted Sep 4, 2007·110 cites·59 claims
- 0294US7070968B2DNA damaging agents in combination with tyrosine kinase inhibitorsDANA FARBER CANCER INST INC·Filed 2003·Granted Jul 4, 2006·35 cites·25 claims
- 0394US6524832B1DNA damaging agents in combination with tyrosine kinase inhibitorsARCH DEV CORP·Filed 1994·Granted Feb 25, 2003·103 cites·9 claims
- 0491US5770581AGene transcription and ionizing radiation: methods and compositionsARCH DEV CORP·Filed 1995·Granted Jun 23, 1998·74 cites·15 claims
- 0591US5612318AControl of gene expression by ionizing radiationFiled 1994·Granted Mar 18, 1997·76 cites·8 claims
- 0690US7247297B2Use of DF3/MUC1 regulated expression in gene therapyDANA FARBER CANCER INST INC·Filed 2002·Granted Jul 24, 2007·30 cites·2 claims
- 0790US6846670B2Genetically engineered herpes virus for the treatment of cardiovascular diseaseUNIV CHICAGO·Filed 2001·Granted Jan 25, 2005·32 cites·28 claims
- 0890US5571797AMethod of inducing gene expression by ionizing radiationARCH DEV CORP·Filed 1994·Granted Nov 5, 1996·87 cites·16 claims
- 0989US7892740B2Prognosis and therapy predictive markers and methods of useUNIV CHICAGO·Filed 2007·Granted Feb 22, 2011·20 cites·23 claims
- 1087US10421971B2Anti-tumor therapyUNIV CHICAGO·Filed 2014·Granted Sep 24, 2019·9 cites·18 claims
- 1187US7838512B2DNA damaging agents in combination with tyrosine kinase inhibitorsARCH DEV CORP·Filed 2006·Granted Nov 23, 2010·2 cites·7 claims
- 1286US9790504B2Anti-tumor therapyKHODAREV NIKOLAI·Filed 2014·Granted Oct 17, 2017·9 cites·5 claims
- 1386US7556935B2Induction of apoptosis by cellular stressDANA FARBER CANCER INST INC·Filed 2006·Granted Jul 7, 2009·9 cites·17 claims
- 1484US9198914B2Methods and compositions for modulating RAD51 and homologous recombinationUNIV CHICAGO·Filed 2013·Granted Dec 1, 2015·5 cites·20 claims
- 1583US8597949B2Methods and compositions for modulating RAD51 and homologous recombinationCONNELL PHILIP P·Filed 2008·Granted Dec 3, 2013·9 cites·11 claims
- 1683US5962424AMethods and compositions for targeting selectinsARCH DEV CORP·Filed 1995·Granted Oct 5, 1999·64 cites·25 claims
- 1780US7041653B2Gene transcription and ionizing radiation: methods and compositionsDANA FARBER CANCER INST INC·Filed 2000·Granted May 9, 2006·4 cites·16 claims
- 1879US6156736AGene transcription and ionizing radiation: methods and compositionsARCH DEV CORP·Filed 1998·Granted Dec 5, 2000·21 cites·41 claims
- 1978US8772261B2Treatment of tumors with genetically engineered herpes virusARCH DEV CORP·Filed 2012·Granted Jul 8, 2014·1 cites·6 claims
- 2076US7118862B2Induction of apoptosis by cellular stressUNIV CHICAGO·Filed 2002·Granted Oct 10, 2006·11 cites·19 claims
- 2173US6605712B1Gene transcription and ionizing radiation: methods and compositionsARCH DEV CORP·Filed 1992·Granted Aug 12, 2003·25 cites·35 claims
- 2272US8318691B2Treatment of tumors with genetically engineered herpes virusWEICHSELBAUM RALPH R·Filed 2010·Granted Nov 27, 2012·1 cites·16 claims
- 2371US8034791B2Activation of Egr-1 promoter by DNA damaging chemotherapeuticsUNIV CHICAGO·Filed 2006·Granted Oct 11, 2011·1 cites·33 claims
- 2471US2025195570A1Methods and compositions for cancer therapyUNIV CHICAGO·Filed 2024·Application pending·0 cites
- 2570US7537894B2Methods and kits for monitoring Barrett's metaplasiaUNIV CHICAGO·Filed 2006·Granted May 26, 2009·1 cites·7 claims
- 2669US6426351B1Chelerythrine-based therapies for cancerDANA FARBER CANCER INC·Filed 2000·Granted Jul 30, 2002·8 cites·30 claims
- 2768US5817636AControl of gene expression by ionizing radiationARCH DEV CORP·Filed 1995·Granted Oct 6, 1998·21 cites·32 claims
- 2867US5641755ARegulation of x-ray mediated gene expressionARCH DEV CORP·Filed 1994·Granted Jun 24, 1997·31 cites·4 claims
- 2967US2025354216A1Methods and systems for molecular subtyping of cancer metastasesUNIV CHICAGO·Filed 2023·Application pending·0 cites
- 3066US2013164811A1Dna damaging agents in combination with tyrosine kinase inhibitorsKUFE DONALD·Filed 2012·Application pending·0 cites
- 3165US6589981B2Tumor radiosensitization and/or chemopotentiation using isocoumarin derivativesILEX ONCOLOGY INC·Filed 2001·Granted Jul 8, 2003·3 cites·4 claims
- 3264US7919310B2Constitutive gene expression in conjunction with ionizing radiationUNIV CHICAGO·Filed 2008·Granted Apr 5, 2011·0 cites·4 claims
- 3364US2019071679A1Anti-tumor therapyUNIV CHICAGO·Filed 2018·Application pending·0 cites
- 3463US2024000741A1All-trans retinoic acid enhances radiotherapy and overcomes immune suppression for cancer therapyUNIV CHICAGO·Filed 2023·Application pending·0 cites
- 3562US2011053240A1Dna damaging agents in combination with tyrosine kinase inhibitorsARCH DEV CORP·Filed 2010·Application pending·0 cites
- 3661US6420335B1Combination of radiotherapy and anti-angiogenic factorsDANA FARBER CANCER INST INC·Filed 1999·Granted Jul 16, 2002·20 cites·28 claims
- 3759US2007281040A1Combination therapy of hedgehog inhibitors, radiation and chemotherapeutic agentsUNIV CHICAGO·Filed 2005·Application pending·0 cites
- 3858US2009093429A1Combination therapy for treating cancerFU YANG-XIN·Filed 2008·Application pending·0 cites
- 3957US2017298362A1Anti-tumor therapyUNIV CHICAGO·Filed 2017·Application pending·0 cites
- 4056US2024175093A1Molecular subtyping of colorectal liver metastases to personalize treatment approachesUNIV CHICAGO·Filed 2022·Application pending·0 cites
- 4155US2004242523A1Chemo-inducible cancer gene therapyANA FARBER CANCER INSTITUE AND·Filed 2004·Application pending·0 cites
- 4255US2003207829A9Treatment of tumors with genetically engineered herpes virusARCH DEV CORP·Filed 2001·Application pending·0 cites
- 4355US2022025004A1Compositions and methods related to site-specific identification of rna modificationsUNIV CHICAGO·Filed 2019·Application pending·0 cites
- 4454US10561708B2Anti-tumor therapyUNIV CHICAGO·Filed 2018·Granted Feb 18, 2020·0 cites·17 claims
- 4554US2013150258A1Prognosis and therapy predictive markers and methods of useUNIV CHICAGO·Filed 2013·Application pending·0 cites
- 4654US2007212298A1Use of the combination comprising temozolomide and tnf-alpha for treating glioblastomaWEICHSELBAUM RALPH R·Filed 2005·Application pending·0 cites
- 4753US2011274661A1Attentuated Herpesvirus Encoding a Mek Pathway PolypeptideUNIV CHICAGO·Filed 2009·Application pending·0 cites
- 4853US2011046211A1Combination therapy of hedgehog inhibitors, radiation and chemotherapeutic agentsUNIV CHICAGO·Filed 2010·Application pending·0 cites
- 4953US2023270861A1Inhibitors of the Artemin Pathway for Treatment of CancerUNIV CHICAGO·Filed 2021·Application pending·0 cites
- 5050US2011200998A1Prognosis and Therapy Predictive Markers and Methods of UseUNIV CHICAGO·Filed 2011·Application pending·0 cites
Showing the top 50 of 69 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Ralph R. Weichselbaum files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →